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Introduction 
 
 
 
INTRODUCTION 
 
             Cancer breast is one of the commonest malignant diseases of 
women next to cancer cervix. It accounts for 30- 40% of all female 
cancers and is responsible for 20% of cancer related deaths in women. 
Since 1940 the incidence is steadily increasing. Breast cancer increases 
with age and it is the most common cause of cancer deaths in women 
over 65 yrs of age.   
           Breast cancer survival depends upon the earliest possible 
diagnosis. 99% cure rates are possible if detected in early stages. Hence 
the present study. 
 
 
 
                                
 
 
                                
 
 
 
 
  
 
 
 
Aim of This Study 
 
 
 
AIM OF THIS STUDY 
 
1. To study about the incidence, epidemiology and environmental 
factors      
         in the genesis of breast cancer in our institution.  
2. To study about various methods for detection of early breast cancer. 
3. To study about the receptor status in early breast cancer patients. 
4. To study about the various histopathological types in early breast 
cancer. 
 
      
                     
                     
 
 
 
 
 
                                 
 
  
 
  
 
 
 
Review of Literature 
 
 REVIEW OF LITERATURE 
        Breast cancer has been observed and studied since time unknown. 
Before the 20th century breast cancer was viewed as a uniformly fatal 
disease without any available or attempted treatment options. The advent 
of Halstedian radical mastectomy in the 20th century was a major advent 
for breast cancer. Since the introduction and widespread use of 
mammography there is an increase in the incidence of detection of small 
localized, non palpable carcinomas of the breast. 
          Now women are coming for treatment with smaller and smaller 
lesions – in the earlier stages which has permitted more conservative 
approach than was necessary in the past. Reducing the extent of surgery 
for early breast cancer in the form of lumpectomy with marginal 
clearance or quadrantectomy might not compromise the outcome.20, 21, 22. 
        Axillary lymph node dissection for clinically negative axilla is 
largely prophylactic, in the current era of lymphatic mapping lymph 
nodal status can readily documented by a lower morbidity procedure – 
sentinel lymph node biopsy. If sentinel lymph node biopsy report comes 
as positive for malignant cells then axillary lymph node dissection can be 
proceeded 38. 
      The benefits of adjuvant systemic therapy in reducing risk of local 
recurrence or distant relapse have been studied for several decades. The 
intent of adjuvant therapy is to eliminate the occult micro metastatis. 
Breast conserving surgery for early stage invasive cancer when combined 
with adjuvant irradiation minimizes the risk of local recurrence.24, 36 
        Early breast cancer patients with ER&PR tumours show a significant 
response to tamoxifen a selective estrogen receptor modulator both in 
terms of local recurrence and distant metastasis. There is also a reduction 
in both the ipsilateral and contralateral breast cancer.29, 30 
      Various trials have shown statistically significant disease free and 
overall survival in patients who receive chemotherapy. Sequential cycles 
of Cyclophosphamide, methotrexate and 5- fluro uracil or Adriamycin 
and cyclophosphamide regimen can be used.1, 17, 24. Chemotherapy plays 
an important role in the management of early breast cancer. Despite all 
these developments it becomes important to individualize patients for the 
best treatment suited to a given women. In the treatment of breast cancer 
we must resort to the methods of the ancients namely , cutting out the 
cancer – surgery, burning it out – radiation or poisoning it - 
chemotherapy  
 
 
 
 
 
EARLY BREAST CANCER 
         The term early breast cancer is applied to tumours of clinical stages            
I and II a. It is an arbitrary distinction but of clinical utility.5, 7 
      The management of early breast cancer is multidisciplinary.                     
Early breast cancer is best managed by considering  
1. Treatment of the breast cancer (treatment of the primary). 
2. Treatment of the reminder of the breast (local therapy). 
3. Treatment of regional lymph nodes of the axilla. (regional 
therapy). 
4. Treatment of possible occult metastatic disease (systemic therapy). 
        Patients with early breast cancer have two options either breast 
conservation surgery with axillary clearance followed by radiotherapy or 
modified radical mastectomy. 
          Assessment of the indications for adjuvant therapy following 
surgery depends on various factors such as size of the tumour, margins of 
the resected tumour, histological grade, lymph nodal involvement and 
receptor status of the patients. Patient must be well informed and 
educated about the advantages and disadvantages of such therapy. 
       
 
 
 
SURGICAL ANATOMY OF THE BREAST 1,2 
      DEVELOPMENT: The epithelial lining of the ducts and acini of the 
breast is developed from ectoderm and the supporting tissue is derived 
from the mesenchyme. On each side of the ventral surface of young 
embryos, a thickened band of ectoderm develops (the milk ridge). It 
extends obliquely from the axilla to the inguinal region. In the human, the 
whole of this ridge disappears, excepting only a small portion in each 
pectoral region from which the breast arise. Nipple is either flat or 
depressed at birth, but later projects beyond the surrounding skin.  
       The breast consists of glandular tissue (mammary gland proper) 
which secretes milk. It also has fibro-fatty tissue between its glandular 
lobes and lobules along with blood vessels, lymphatics and nerves 
covered by skin. 
EXTENT: Vertical:      2nd to 6th rib.                                            
                 Horizontal:  The side of the sternum to the midaxillary line. 
         It lies over the pectoralis major, seratus anterior and aponeurosis of 
external oblique from which it is separated by a dense fascia with 
superficially intervening loose connective tissue (retromammary space). 
(Fig.1)  
NIPPLE AND AREOLA: Cylindrical (or) conical projection at the 
anterior mammary aspect at the level of 4th intercostal space (nullipara). It 
is pink (or) dark in colour, traversed by 15-20 lactiferous ducts.  
 
SURGICAL ANATOMY OF BREAST Fig.1 
 
 
 
 
Fig .2 
 
 
 
 
 
 
 
 
 
 
It contains circular (erection) and longitudinal (retraction) muscle 
fibres. Its base is encircled by a cutaneous discoidal area, the areola- rose 
pink in colour (nullipara). It becomes darker during pregnancy.    
AXILLARY TAIL OF SPENCE: Prolongation of outer part of the gland 
at the level of 3rd rib into axilla. It is deep to deep fascia. 
 STRUCTURE OF BREAST: It is composed of acini which are made up 
of lobules which form the lobes of the gland (Fig.2).  Each lobe is drained 
by a duct, 10 -15 ducts open onto the nipple. Each portion of ducts 
involved in different disease.Major duct - duct papilloma and duct 
ectasia, distal smaller ducts – fibroadenoma, cyst formation and 
sclerosing adenosis, intra lobular portion of terminal ducts – carcinoma. 
LIGAMENTS OF COOPER: These are bands of connective tissue which 
anchors the skin on the pectoral fascia. Infiltration of this by malignant 
cells causes dimpling of the skin. 
BLOOD SUPPLY: Breast is supplied by 
1) Lateral thoracic artery from 2nd part of axillary artery. 
2) 2nd, 3rd & 4th perforators of internal mammary artery. 
3) Lateral branches of 2nd, 3rd & 4th intercostal arteries. 
VENOUS DRAINAGE:  It is to the axillary, internal mammary and 
intercostal veins. 
NERVE SUPPLY: Sympathetic nerves supply the secreting tissue via 2nd 
to 6th intercostal nerves. Skin is supplied by 4th to 6th intercostal nerves. 
LYMPHATIC DRAINAGE (Fig.3): Skin lymphatics of breast except 
areola and nipple drain into axillary nodes. From the upper part it drains 
into to supraclavicular nodes. From the medial part it drains into internal 
mammary nodes. 
           The subareolar lymph plexus of sappey is a collection of large 
lymph vessels under the areola. Most of the lymphatics go to anterior 
group, few pass to the posterior group. From here they run to central and 
apical groups. 
          From the deeper surface, vessels pierce through pectoral muscle to 
the axillary and internal mammary nodes. From the medial and inferior 
part of breast lymph vessels drain into internal mammary nodes. At the 
level of first interspace, fine lymphatics connect right and left internal 
mammary chains behind the manubrium sterni. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LYMPHATICS OF BREAST Fig.3 
 
 
 
 
 
 
SURGICAL PATHOLOGY 
CARCINOMA OF THE BREAST 3, 4, 5 
     NON INVASIVE (INSITU) CARCINOMA 
A). Ductal carcinoma in situ (DCIS): With the advent of mammography, 
it now constitutes 22-80% of carcinomas.  It is defined as malignant 
population of cells that lack the capacity to invade the basement 
membrane and incapable of distant metastasis. There are five subtypes -
comedo carcinoma (more malignant),Solid, 
Cribiform,Papillary,Micropapillary. 
B). Lobular carcinoma insitu (LCIS): There is proliferation of loosely 
cohesive cells in one or more terminal ducts / acini. It is frequently 
multifocal and bilateral. It is a marker for invasive carcinoma. 
                                  INVASIVE CARCINOMA 
A). Invasive ductal carcinoma: It is the most Common type. It constitutes 
65-80% of all mammary cancers. There may be lump breast (Fig.4), 
nipple discharge(Fig.5),  nipple retraction, dimpling of skin or fixity to 
the chest wall muscles. Histologically malignant duct lining cells 
disposed in cords, solid cell nests, tubular glands or anastamosing masses. 
  B). Medullary carcinoma:  Incidence 1-5% do not have striking 
desmoplasia. Histologically solid syncytium like sheets of large cells with 
lymphocytic infiltration is present. 
 
EARLY BREAST CANCER – LUMP LT BREAST Fig .4 
 
 
 
 
 
NIPPLE DISCHARGE Fig.5 
 
 
  C). Colloid or mucinous carcinoma: Occurs in old women, slow 
growing, histologically large lakes of amorphous mucin with scattered 
neoplastic cells are present. 
  D). Pagets disease:  It involves the nipple and areola. There is invariably 
underlying ductal carcinoma in situ. Histological hallmark is large 
vacuolated cells with eccentric nuclei, involvement of epidermis by 
malignant cells. 
  E). Invasive lobular carcinoma: Peculiar feature is bilateral and 
multicentric. Histologically it consists of strands of infiltrating tumour 
cells, loosely disposed throughout the fibrous matrix. 
   F).Sarcomas: Usually solid tumours, there may be cystic degeneration. 
Examples of sarcomas are fibrosarcoma, liposarcoma & stromal sarcoma. 
Histologically spindle cells are seen. 
   G). Lymphomas: Primary lymphomas are rare. There is predominance 
of diffuse histiocytic lymphomas. 
    H). Inflammatory carcinoma: This type of carcinoma is usually 
mistaken for breast abscess. Clinically erythema, peau d’ orange will be 
there. The subdermal lymphtics and vascular channels are permeated by 
tumour cells. Polymorphs and lymphocytes are absent near the tumour. It 
has fast metastatic potential. 
 
 
MODES OF SPREAD 8, 9 
 Breast cancer spreads by all means 
1. Local spread 
2. Lymphatic spread 
3. Blood spread 
4. Trans coelomic spread 
  Local spread: By local extension the tumour increases in size and 
invades the surrounding tissue. Thus infiltration of Cooper’s ligament 
causes dimpling of skin. Outward growth can ulcerate and fungate. 
Inward growth leads to fixity to deeper structures like pectoral muscles 
and chestwall.  Lymphatic spread: It occurs by two means 
a. By embolus- in which the cancer cells are swept in lymphatic vessels 
to distant nodes. 
b. By permeation- the cancer cells grow in columns inside the lymphatic 
lumen to the draining nodes.    
Sentinel lymph node 38: the axillary nodal status is the most powerful 
prognostic tool available for early breast cancer. Breast cancer spreads 
from the tumour bed to one or a few lymph nodes – the sentinel lymph 
nodes, before it spreads to other axillary nodes. These sentinel lymph 
nodes can be identified by lymphatic mapping techniques by using radio 
isotope technetium 99 sulphur colloid and a hand held gamma probe. 
Methylene blue also has been successful in SLNB for breast cancer. 
Patients who have negative sentinel lymph nodes are safely spared of 
axillary dissection.                     
       Axillary in the order of level I to level III and internal mammary 
nodes are affected early. The first node to get involved is the sentinel 
node. Supraclavicular nodes, mediastinal nodes and contralateral nodes 
and cotralateral breast involve very late. 
       Blood spread: Spread by bloodstream cause distant skeletal and 
visceral metastasis. Skeletal metastasis are common in lumbar vertebra, 
femur, thoracic vertebra and skull. Pathological fractures are common in 
ribs and vertebra, the secondaries are commonly osteolytic. Lung, liver 
and brain are also involved in metastasis in later stages. Liver metastasis 
occur through the lymphatics in the rectus sheath and the falciform 
ligament. 
 Transcoelomic spread: Cancer cells are shed into the coelomic cavity and 
settle on the ovaries to cause secondaries. 
 
                    SCREENING FOR EARLY BREAST CANCER 
       The goal of cancer screening is early detection of malignancy at a 
stage that will lead to a reduction in mortality and morbidity 7, 15. For 
breast cancer the ideal screening programme should be sensitive enough 
to detect occult cancers with a minimum of false positive findings. 
Current recommendations for screening of women with breast cancer 
include 
1. Monthly breast self examination (Fig.6). 
2. Clinical breast examination every 4-6 months. 
3. Annual mammography for all patients above 40 yrs and for high risk 
patients above 35yrs5. 
       Additional modalities such as ultrasonography, breast MRI, ductal 
lavage are currently under investigation. 
        Several studies suggest that MRI is more sensitive than 
mammography in the population. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BREAST SELF EXAMINATION Fig.6 
 
 
 
 
CLINICAL BREAST EXAMINATION Fig.7 
 
 
 
                       CLINICAL BREAST EXAMINATION:             
  Inspection: The women presenting with breast lump is examined with 
her arms by her side, with her arms straight up above her head, and with 
her hands on her hips (with and without pectoral muscle 
contraction).Symmetry, shape and size of the breast are recorded, as well 
as any evidence of oedema, nipple or skin retraction and erythema. The 
woman has to lean forward to accentuate any skin retraction. 
           Palpation (Fig.7): The breast is carefully palpated. The surgeon 
gently palpates the breast from the ipsilateral side making certain to 
examine all quadrants of the breast from the sternum to the lattismus 
dorsi muscle laterally and from the clavicle to the upper rectus sheath 
inferiorly. The surgeon performs the examination with the palmar aspect 
of the fingers avoiding a grasping or pricking motion. The breast may be 
cupped or moulded in the surgeon’s hands to check for retraction. A 
systemic search for lymphadenopathy is then performed by supporting 
the upper arm and elbow. The shoulder girdle is stabilized. Using gentle 
palpation all three levels of possible axillary lymphadenopathy should be 
assessed. Careful palpation of infraclavicular and parasternal sites is also 
performed. 
 
 
 
 RISK FACTORS FOR BREAST CANCER33 
Factors important in population: Age at menarche and menopause, parity, 
age at first child birth, breast feeding, use of exogenous hormones, 
alcohol consumption. 
Factors important in individual patients: Gender (female), age (steady 
increase with age), family history of breast cancer (mother, sisters, 
daughters), history of previous breast cancer (noninvasive or invasive, 
ipsilateral or  contralateral). 
Histological risk factors: Proliferative breast disease, atypical ductal 
hyperplasia, atypical lobular hyperplasia, carcinoma in situ.       
 
 
 
 
 
 
 
 
 
 
 
PROGNOSTIC FACTORS 
            A prognostic factor is defined as any measurement taken at the 
time of surgery or diagnosis that is associated with outcome (overall 
survival, disease free survival or local control).34, 35 
           1.   Tumour size. 
2. Axillary nodal status. 
3. Histological grade. 
4. ER-PR status. 
5. Age, menopausal status, vascular invasion etc., 
NOTTINGHAM’S PROGNOSTIC INDEX 
NPI = (tumour size in cm x 0.2) + lymph node stage + grade of tumour. 
Prognostic group          NPI             10yrs survival % 
Excellent                <or=2.4           94   
Good                      <or=3.4           83 
Moderate I              <or=4.4          70 
Moderate II             <or=5.4           51 
Poor                            > 5.4            19  
                       
 
 
 
 
PROPHYLAXIS OF BREAST CANCER 
          The women who are at risk of developing breast cancer i.e. patients 
with strong family history of breast cancer, patients who are positive for 
BRCA 1 and BRCA 2 genes, patients with atypical hyperplasia, lobular 
carcinoma in situ and with predisposing factors for breast cancer can be 
given prophylactic therapy for breast cancer. These include prophylactic 
chemoprevention, prophylactic mastectomy and prophylactic bilateral 
salpingo oophorectomy.  With prophylactic therapy there is a reduction in 
the development of breast cancer, reduction in the development of 
recurrence and reduction in the development of contralateral breast 
cancer. 
          Prophylactic drug therapy: Selective estrogen receptor modulators 
like tamoxifen can be used in the dose of 10mg twice daily31. Roloxifene 
and Fenesteride are also being used.  
          Prophylactic surgery: Prophylactic bilateral mastectomy is done in 
high risk patients 31, 39. The risk reduction due to bilateral prophylactic 
mastectomy was estimated as 85% - 100% in the recent Prevention and 
observation of surgical end point (PROSE) study of Rebbeck and 
colleagues. 
         Prophylactic bilateral salpingo oopharectomy has also been proved 
to be useful in prophylaxis of breast cancer. 
 
INVESTIGATIONS 26, 27 
Basic Investigations: Blood: Hb%, total count, differential count, ESR, 
Grouping and Rh typing, sugar, urea. 
Urine: Albumin, sugar, deposits      
Serum: Creatinine,  cholesterol, liver function tests. 
X-RAY Chest PA view, ECG,ultrasound abdomen and pelvis. 
Investigations to Confirm the Diagnosis: Mammography, 
mammography guided biopsy, USG of the breast (Fig.8) and guided 
biopsy, MRI of the breast (Fig.9) and guided biopsy, fine needle 
aspiration cytology, core needle biopsy, incision biopsy, excision biopsy. 
Investigations to Rule out Secondaries: 
X-Ray spine and long bones, USG abdomen and pelvis, CT brain, MRI, 
radio isotope bone scan Tc99m, radio isotope liver scan. 
Investigations For Prognosis: 
Hormone receptor assay for ER&PR status, tumour marker studies,DNA 
Ploidy analysis, Proto-oncogene c-erb-2 studies, cathepsin D level 
estimation, epidermal growth factor / receptor study.    
            
 
 
 
 
 
 
 
 
 
USG BREAST WITH CALCIFICATION Fig.8 
 
 
 
EARLY BREAST CANCER – MRI Fig.9 
 
 
                                           
                                           MAMMOGRAPHY 
           Soft tissue radiographs are taken placing the breast in direct 
contact with ultrasensitive film and exposing it to low voltage, high 
amperage X- Rays. The sensitivity of this investigation increases with age 
as the breast becomes less dense. Screening mammography is used to 
detect unexpected breast cancer in asymptomatic women15, 16. It 
supplements history and physical examination. 
           In mammography two views of the breast are obtained. The 
craniocaudal view and the mediolateral oblique view. Mammography is 
also used to guide interventional procedures including needle localization 
and needle biopsy. 
          Specific mammographic features that suggest a diagnosis of breast 
cancer include a solid mass with or without stellate features, asymmetric 
thickening of breast tissues and clustered microcalcifications. The 
microcalcifications (Fig.10) are an especially important sign of cancer in 
young women- it may be the only mammographic finding. 
The presence of fine stippled calcium in and around a suspicious  
 
lesionand spiculations (Fig.11) are suggestive of breast cancer.     
 
 
 
 
 
 
 
 
  
 
MAMMOGRAM WITH MICROCALCIFICATION Fig.10 
 
 
 
 
 
MAMMOGRAM WITH SPICULATION Fig.11 
 
  
 
  Mammography is more accurate than clinical examination for detection 
of early breast cancer providing a true positive rate of 90%. 
        Xeromammography techniques are identical to those of 
mammography with the exception that the image is recorded on a 
xerography plate which provides a positive rather than a negative image. 
Details of the entire breast and the soft tissues of the chest wall may be 
recorded with one exposure.  
 
    BI- RADS GRADING OF MAMMAOGRAPHIC 
ABNORMALITY10 
      Category                                                   Definition 
1 Negative for malignancy 
2 Suggestive of benign lesion 
3 Suspicious of benign lesion 
4 Suspicious of malignant lesion 
5 Highly suggestive of malignancy. 
   
                       
 
  
                      
               FINE NEEDLE ASPIRATION CYTOLOGY 
         Fine needles particularly 23 or 24 gauze with a 2.54-3.8 cms length 
along with 10 or 20 cc syringe is used for aspiration.  
        The aspirated material is smeared over the slides. Either the smear is 
air dried or a fixative containing ether alcohol mixture can be used3, 4. 
Technique: 
         It is not necessary to prepare the patient for aspiration. No 
anaesthesia is required as the pain experienced is small and well tolerated. 
          The palpable lesion is fixed with one hand. Skin is cleaned and the 
needle is inserted into it (Fig.12). Full suction is applied. Needle tip is 
moved around. Piston is allowed to fall back to neutralize the pressure in 
the syringe and then the needle is withdrawn. Material is expressed onto 
the glass slide. Smears are prepared and fixed.  
                                    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FNAC TECHNIUE Fig.12 
 
 
 
 
                                 
 
 
                          TRUCUT NEEDLE BIOPSY 
         Disposable trucut needle or metal trucut needle can be used. 
Technique: The palpable lesion is fixed with two hands of an assistant. 
The skin is cleaned and local anaesthesia is infiltrated. The needle is 
inserted and as soon as the lump is reached the needle is advanced 
(Fig.13). Once the inner needle is inside the mass the outer needled is 
pushed and whole trucut withdrawn. The material inside the stillet is 
taken and sent for HPE4, 6, 7. 
Advantages: It is quick, requires no special apparatus and technically 
easy. 
1. In out patient department, it can be done under local 
anaesthesia.(care must be taken not to alter the morphology of the 
cells by using large volumes of LA). 
2. In advanced cancers, whose excision or incision is contraindicated, 
trucut biopsy is ideal to confirm the diagnosis and keep permanent 
record of the type of cells present. As there is no damage to the 
skin, radiotherapy can be given at once. 
3. Causes of failure: 
Failure to insert the needle into the tumour especially when the tumour is 
small and the breast is large and fatty, Blocking of the needle with fat, 
Local anaesthetic, if used may dilute the specimen, Faulty location and 
training.For proper interpretation adequate smear is essential.  
                                
 
 
 
 
 
 
 
 
         TRU-CUT BIOPSY Fig.13 
 
 
 
 
 
 
 
 
 
 
HORMONE RECEPTORS 
         A predictive factor is any measure that predicts response or lack of 
response to a specific treatment. Estrogen and progesterone receptor 
status are the most important and helpful currently available predictive 
factors to assess the response to tamoxifen.5, 15, 17  
        Crucial development in the evaluation of breast cancer was the 
realization of the presence of hormone receptors (estrogen and 
progesterone) in the tumour tissue that correlates with response to 
hormone therapy. 
        Traditionally these hormone receptors were measured by dextran 
coated charcoal and sucrose gradient assay. Now replaced by 
immunohistochemical method on the grounds that it offers several 
important advantages 
                    - It does not require fresh tissue. 
    - It can be done with minute amounts of tumour. 
         The two parameters evaluated in immunohistochemical preparations 
of hormone receptors are     
        1. The number of tumour cell nuclei stained - expressed as a 
percentage of entire tumour cell nuclei population. 
 2. The intensity of the reaction - is graded as negative, weak, moderate 
and strong. The two parameters are sometimes combined into a scoring 
system. 
.          Hormone receptors can also be evaluated in paraffin embedded 
breast tissue by insitu hybridization technique and by polymerase chain 
reaction. No statistically significant difference has been found between 
ductal type and lobular type tumours. However most medullary 
carcinomas, intraductal carcinoma of comedocarcinoma type are negative 
for receptors whereas mucinous carcinoma has the highest rates of  
positivity. 
              Generally estrogen receptor concentrations are lower in tumours 
of premenopausal women than those of postmenopausal women Fisher et 
al found the presence of estrogen receptor to be significantly associated 
with high nuclear and low histologic grades, absence of tumour necrosis, 
presence of marked tumour elastosis and in patients of older age group.  
           HER 2/ neu: HER 2/ neu is an oncogene that encodes a 
transmembrane glycoprotein with tyrosine kinase activity known as P 185 
which belongs to the family of epidermal growth factor receptors. Its 
overexpression measured by immunohistory. Overall expression of HER 
2/neu is avery good predictor of response to Herceptin but not to overall 
survival. 
 
                 
 
 
                                  STAGING OF BREAST CANCER 
 
    Method of staging: Performed initially on a clinical basis according to 
physical examination, laboratory and radiological evaluation 5, 9. 
1. Comprehensive history and physical examination. 
2. Bilateral breast imaging (mammography / 
xeromammography). 
3. Laboratory evaluation including haemogram and hepatic 
function. 
4. X- ray chest PA and LATERAL views. 
           5. Skeletal X- ray survey (indicated if there is bony pain). 
           6. USG abdomen for all cases, abdominal CT and radionuclide 
bone scan if necessary. 
 
 
 
 
 
 
                                    
 
                                      
   TNM CLASSIFICATION: 
Primary tumour (T) 
TX –Primary tumour cannot be assessed. 
TO- No evidence of primary tumour. 
Tis – Carcinoma in situ (intraductal carcinoma, lobular carcinoma in situ, 
pagets disease of nipple with no tumour). 
T1 – Tumour < or = 2cms in greatest dimension. 
        T1(a) - < or =0.5 cm in greatest dimension. 
        T1(b) ->0.5 cm but < 1 cm in greatest dimension. 
        T1(c) ->1cm, but not > 2cm in greatest dimension.  
T2 – Tumour> 2cm, but not > 5cm in greatest Dimension. 
T3 – Tumour >5cm in greatest dimension. 
T4 – Tumour of any size with direct extension to chest wall or skin. 
        T4(a) – extension to chest wall. 
         T4(b) – Edema (including peau d’ orange) or Ulceration of the skin 
of      breast or satellite Skin nodules confined to same breast. 
         T4(c) – Both T4 (a) & T4(b). 
          T4(d) – Inflammatory carcinoma. 
 
 
 
 
Nodal staging: 
NX –Regional lymph nodes cannot be assessed 
         (e.g.,    previously removed or not removed for pathologic study). 
NO – No regional lymph node metastasis. 
N1 – Metastasis to movable ipsilateral axillary lymph node(s). 
 N1(a) –Only micrometastasis (none larger than 0.2cm). 
 N1(bi) – Metastasis in 1-3 lymph nodes, >0.2cm and < 2cm in greatest 
dimension 
 N1(bii) – Metastasis to 4 or more lymph nodes,>0.2cm and >2cm in 
greatest dimension. 
 N1(biii) – Extension of tumour beyond the capsule of a lymph node 
metastasis <2cm in greatest dimension. 
  N1(biv) – Metastasis to lymph node 2cm or more in greatest dimension. 
N2 – Ipsilateral fixed nodes. (or) Internal mammary nodes. 
N3 – Ipsilateral supraclavicular Lymph nodes. 
 
 
 
 
 
 
 
Distant metastasis:  
MX – Presence of distant metastasis cannot be assessed. 
MO –No distant metastasis. 
M1 – Distant metastasis present.  
 
AMERICAN JOINT COMMITTEE ON CANCER 
STAGE GROUPING 11 
         Stage 0          Tis N0 M0 
        Stage I           T1 N0 M0 
        Stage II A      T0 N1 M0, T1 N1 M0, T2 N0 M0 
        Stage II B       T2 N1 M0, T3 N0 M0 
        Stage III A    TO N2 M0, T1 N2 M0, T2 N2 M0, T3 N1 M0,     
                              T3N2M0 
        Stage III B     T4 any N  M0, Any T N3  M0 
         Stage IV        Any T Any N  M. 
                                         
 
 
 
 
                                    
 
                   MANCHESTER STAGING 13 
Stage I - Growth confined to breast, skin involvement less than tumour 
size. 
Stage II - Growth confined to the breast, skin involvement less than 
tumour size, palpable mobile ipsilateral lymph node in axilla. 
Stage III - Growth extending beyond mammary parenchyma. 
a. Skin involvement more than the tumour size with mobile ipsilateral 
axillary nodes. 
b. Tumour fixed to underlying muscle or fascia with  Mobile ipsilateral 
axillary nodes. 
Stage IV – Growth beyond breast area shown by complete fixation of 
tumour to chest wall, fixed ipsilateral axillary lymph nodes, deposits. 
supraclavicular nodes or in opposite breast, satellite nodules or distant 
metastasis.            
 
 
 
 
 
 
 
 
TREATMENT OF STAGE I & II (EARLY) 
BREAST CANCER 
These patients are divided into 3 risk groups. Treatment depends upon 
which group they come under 5, 13, 16 
Low risk group: Tumour less than 1 cm in size, well differentiated 
tumour, and ER + ve tumours – local surgery and followup alone. 
Intermediate risk group: Tumour size 1-2 cms , well differentiated 
tumours and ER+ ve irrespective of menopausal age – local surgery + 
hormonal therapy. 
High risk group: Tumour more than 2cms in size or 1-2 cms in size but 
ER –ve  and poorly differentiated tumours – local surgery + systemic 
chemotherapy. 
              SURGICAL MODALITIES FOR EARLY BREAST 
CANCER                                                               Breast Conservation 
Surgery18, 20 (Fig14): 
Lumpectomy: It involves removal of clinically palpable tumour mass. 
But microscopical clearance of surgical margins is not possible. 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
 
 
 
 
 
 
 
 
 
BREAST CONSERVATION WITH AXILLARY CLEARANCE 
Fig.14 
 
 
 
 
 
 
 
 
 
 Wide excision: It is otherwise called segmentectomy, partial mastectomy 
or tylectomy. It involves removal of tumour proper and a rim of clinically 
normal breast tissue. 
Quadrantectomy: Removal of 2 – 3 cms of adjacent breast tissue and 
skin over the tumour of the affected quadrant of the breast. 
Quadrantectomy+ axillary clearance+ radiotherapy – QUART therapy. 
MASTECTOMY13, 18: 
Simple mastectomy: It means complete removal of the breast and 
axillary tail leaving the axilla undisturbed. But few anterior axillary group 
of nodes attached to the axillary tail is also removed.  
Modified radical mastectomy (Auchincloss’s) (Fig15-18):   In this 
procedure the pectoralis minor is not removed or divided, because only 
2% of the patients are benefited by dissection of level III nodes. 
Modified radical mastectomy (Patey’s): In this method simple 
mastectomy is done with axillary clearance. Pectoralis minor is removed 
to reach the upper 2/3rd of the axilla. The pectoralis major muscle is 
preserved to improve the function and appearance. 
Modified radical mastectomy (Scanlon’s): Here the pectoralis minor 
muscle is just divided but not removed. This permits easy removal of 
level III nodes, and the lateral pectoral nerve to pectoralis major is also 
preserved. 
 
 
OBLIQUE MRM INCISION Fig.15 
 
 
 
 
 
 
 
 
REMOVAL OF BREAST TISSUE WITH PECTORAL FASCIA Fig.16 
 
 
 
 
 
 
 
 
 
 
 
LT MRM SPECIMEN Fig.17 
 
 
 
 
LT AXILLARY DISSECTION Fig.18 
 
 
Breast reconstruction: Breast reconstruction after mastectomy has 
become an important part of comprehensive treatment for patients who 
have breast cancer40. It can also improve the psychosocial wellbeing and 
quality of life of patients who have breast cancer. This process can start at 
the time of the mastectomy (immediate reconstruction) or any time 
afterwards (delayed reconstruction). 
            Transverse rectus myocutaneous TRAM flap (Fig.19) or lattismus 
dorsi myocutaneous LD flap can be used for breast reconstruction.Finally 
nipple and areola can be reconstructed. 
 
 
 
RT MRM WITH TRAM FLAP RECONSTRUCTION Fig.19 
 
 
 
 
 
 
 
CHEMOTHERAPY 
           The various clinical trials of National surgical adjuvant breast 
project demonstrated that surgery followed by adjuvant chemotherapy 
yielded superior results to either modality alone19, 24. Despite 
improvements in loco-regional control the predominant pattern of failure 
in breast cancer is distant metastasis. The probability of distant 
dissemination is strongly associated with the rate of axillary node 
involvement (micrometastatic disease).                                                                            
                Empirical and practical considerations were used in the 
selection of chemotherapeutic agents, the treatment schedule and the 
duration of treatment. The selection of drugs and the treatment schedule 
(typically given in cycles) must achieve a net reduction in the cell burden 
by the time to deliver the next cycle, and the optimal treatment intensity 
must be at least as intense as that which yields the optimal results. 
The use of combination of drugs is superior to the use of single agent and 
can eradicate 10-100 times as many cells. In transplantable tumours, 
surgical adjuvant chemotherapy increases the long term cure rates. The 
efficacy of chemotherapy is dose dependant related to the tumour cell 
burden at the time of drug treatment and to the presence of primary 
resistant tumour cells.  
 
       Operable breast cancer is often a systemic disease and variations in 
loco-regional therapy are unlikely to substantially affect survival. Only by 
control of distant metastasis can there be an improvement in the outcome 
of breast cancer patients.               
     A number of new drugs have been tried especially towards treatment 
of metastatic cancer of the breast. Taxol a microtubule agent (paclitaxel 
and docetaxel) in combination with doxorubicin have been found to be 
very effective in the treatment of advanced breast cancer. 
     Non-specific immunotherapy in the form of levamizole and BCG has 
been tried in the past in the management of advanced breast cancer, now 
been found to be largely ineffective.     
                  
                 
 
 
 
 
 
 
 
 
 
CHEMOTHERAPY REGIMENS FOR BREAST CANCER24 
   
                                Regimens  
       Drug Classic CMF       CMF     AC       FAC 
Cyclophosphamide 
 
Methotrexate 
 
5-Fluorouracil 
 
Adriamycin 
 
 
Cycle freqency 
 
100 oral 
days 1- 14 
40  IV     days 
1&8 
600 IV 
days1&8 
 
 
 
Once in 4wks 
600 IV 
day 1 
40 IV   day1
 
600 IV 
day1 
 
 
 
Once in 
3wks 
600 IV 
day 1 
 
 
 
 
60IV 
day1 
 
Once in 
3wks 
400-500IV 
day 1 
 
 
400-500 IV 
days1&8 
40-50IV 
day1 
 
Once in 4wks 
 
Drug doses in mg/sq. mt body surface area 
Surface area in Sq.metre = 0.007184 * wt. in kg 0.425/ Ht in cm 0.725                           
 
 
                      
 
 RADIOTHERAPY 
 Combination of RT and surgery: 
     Modes of failure of two are different. RT is highly effective at the 
periphery of the tumour where the cell number is less. RT failure occurs 
at the centre where a large number of cells are in hypoxic state. 
     Surgical failure is usually due to remnant tumour cell at the periphery 
being left in the body by inadequate resection or limitation of resection by 
adjacent vital organs. So combination of RT and surgery helps in 
overcoming this problem.16, 22 
Preoperative RT: The tumour margins are sterilized. But the destruction 
of cells by RTwill prevent the correct assessment of initial extent of 
tumour , intra operative staging is impaired. 
 Postoperative RT: Patients who are going to benefit from RT can be 
determined. Unnecessary exposure is avoided. 
 BREAST CANCER AND RT: 
     Megavoltage electron beam or co 60 used for dose homogenicity and 
skin sparing. Breast is irradiated by tangentially directed fields. Total 
dose of 4500 to 5000 rads given fractioned to 180 to 200 rads 5 days a 
week for 5 to 5 ½ weeks. 
     
            Booster doses may be given at the conclusion of RT in which the 
total dose is increased to 6000 rads. 
          Axillary dissection is a contraindication to RT to axilla due 
increased complications and the fact that less than 1% of patients who 
had undergone axillary dissection have treatment failure due to local 
recurrence in axilla. Microscopic extranodular extension is of no 
significance. Undissected axilla indicated cases will receive 40-50 rads,  
ie., clinically positive nodes morethan 4 in number. 
INDICATIONS: Definite: Positive margins of mastectomy specimen or 
gross residual disease, T3 tumour especially if N+, Any T4 tumour, gross 
extracapsular lymphnode disease. 
Relative: Surgical margin of 1-2 mm only, 4 or more nodes especially 
postmenopausal. 
 RT In stage I & II breast cancer: Breast conservation surgery   - After 
lumpectomy RT is given for the remaining breast tissue.                      
  Adjuvant RT: Chest wall recurrence is seen in 5%-10% of node negative 
and 15%-20% of node positive patients. Adjuvant RT is highly effective 
in reducing the local recurrence to less than 5% Survival is definitely 
improved in node positive & medial quadrant tumours receiving adjuvant 
RT. 
 
 
 
 
HORMONE THERAPY 
         Response rates of breast cancer to hormonal treatment with respect 
to activities of ER & PR 24, 29, 30       
            RECEPTOR STATUS   RESPONSE (%) 
         ER+             PR+          78 
         ER+             PR+          34 
         ER-             PR-          10 
         ER-             PR+          45 
 
  ER = Oestrogen receptor 
  PR = Progesterone receptor  
Patients with invasive breast cancer whose tumours are totally lacking in 
estrogen and progesterone receptors donot respond to or derive benefit 
from hormonal manipulations. The benefits of tamoxifen in DCIS have 
been shown to be restricted to patients with hormone receptor positive 
tumours.  
          Studies from the early breast cancer triallists collaborative group 
(EBCTCG) overview analysis suggest that even patients whose tumours 
have as few as 1% of cells staining positively for hormone receptors may 
derive benefit from adjuvant endocrine therapy. For these reasons it is 
most appropriate to have ER and PR expression reported as percentage of 
cells stained for each receptor. 
           At 5 yrs after diagnosis women with ERand PR positive tumours 
have a relapse rate of  5%-10% superior to that of patients with ER 
negative tumours, but this advantage decreases and ultimately disappears 
with increasing time of follow up. 
         Tamoxifen therapy significantly decreased the risk of dying of 
breast cancer among patients with ER positive tumours compared to those 
with ER negative and PR negative tumours. 
         Discovery of tamoxifen , a non steroidal selective oestrogen 
receptor modulator which has low toxic effect, is the first line of 
treatment for patients with hormone responsive breast cancer. It competes 
with circulating oestrogens for binding to oestrogen receptor protein. This 
blockage accounts for atleast some of it’s antiproliferative activities. The 
standard dose of tamoxifen is 20mg/day. It has a half life of 7 days and 
takes four weeks to reach a steady state in the plasma. There is no 
evidence that prolonging treatment beyond 5 yrs may produce any 
benefit. Since introduction in 1970 tamoxifen has replaced previously 
prescribed drugs like oestrogens and androgens. Though generally well 
tolerated side effects like menopausal signs and symptoms, nausea, 
thrombophlebitis, ocular abnormalities and endometrial carcinoma have 
been reported. 
Leutinising hormone releasing hormone analogues like leuperolide, 
goserelin, buserelin are promising new drugs in the hormonal treatment 
of breast cancer. These agonist drugs decrease follicle stimulating 
hormone and prolactin secretion as well as circulating levels of sex 
hormones resulting in medical equivalent of oophorectomy. 
  Progestational agents like medroxy progesterone acetate and 
megestral acetate are widely used. The mechanism of action though not 
clear, these drugs are used in metastatic disease as some patients show 
response to these drugs, as a second line hormonal therapy with 
tamoxifen32.  It is now well understood that in postmenopausal women 
oestrogen are largely produced by aromatization of adrenal androgens 
and that aromatase inhibitors ( anastrazole, letrazole) can exert an anti-
tumour effect in breast cancer. 
      Aminoglutethemide has shown to inhibit several types of adrenal 
steroid synthesis and the aromatase mediated peripheral conversion of 
adrenal androgen to oestrogen. However the side effects have been 
considerable. Currently the standard approach is 250mg of 
aminoglutethamide twice daily.                                                
 
                                                   
 
 
 
 
                                          FOLLOW UP 
           With improving outcomes in breast cancer treatment there is a 
growing population of breast cancer survivors who are living to older 
ages. Most recurrences or metastasis are diagnosed on the basis of 
symptoms and physical findings5, 6. Biochemical testing and imaging are 
not of much importance. Patients are educated about symptoms and signs 
of recurrences (Fig.20) at the completion of therapy. 
1.Monthly breast self examination both breasts in patients who 
underwenbreast conservation surgery and contralateral breast in patients 
who underwent modified radical mastectomy. 
2.Clinical breast examination every 3-6 months for the first 3 years, every 
6-12 months for the next 2 years and then annually for the lifetime. 
3.Mammography of the ipsilateral breast (remaining after lumpectomy)- 
once in 6 months, contralateral breast annually. 
4.Imaging of chest and abdomen annually for 3 years. 
      CT brain and radionuclide bone scan are not routinely done 
during follow up of breast cancer patients. Patients should continue 
their routine health maintenance evaluation. They should report if 
there is any new symptoms such as new lump, pain, dyspnoea, 
weight loss, etc 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RT MRM SCAR Fig.20 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Materials and Methods 
 
 
 
MATERIALS AND METHODS 
           This was a prospective study which consisted of patients admitted 
to all surgical units of COIMBATORE MEDICAL COLLEGE 
HOSPITAL, COIMBATORE with early breast cancer from august 2006 
– September 2008. 
          A complete clinical evaluation of the case including history, 
general physical examination and clinical breast examination was done. 
         Necessary investigations were done to confirm the diagnosis, stage 
the disease and for definitive treatment. Fine needle aspiration cytology 
was done for all cases to confirm the diagnosis. Routine blood 
investigations, chest x-ray and ECG were done for all cases. Bilateral 
mammogram, liver function tests and ultrasound abdomen was done to 
stage the disease. 
        For loco regional control modified radical mastectomy with or 
without oophorectomy was done. Adjuvant therapy in the form of 
Chemotherapy, hormone therapy or radiotherapy was given depending 
upon the lymph nodal status and receptor status. Periodical follow up of 
all cases were done to assess the local and systemic metastasis. 
 
      
 
 
  
 
 
 
Results and Discussion 
 
 
 
RESULTS AND DISCUSSION 
  During the period of study from august 2006 – September 2008 a 
total number of 186 breast cancer cases attended our   institution. Out of 
this, 33 patients 17.7% of cases presented with early breast cancer. This 
study was consistent with that of FisherB, Je ong JH, Dignam J, et al. 
early breast cancer 15- 20%.16 
        STAGE WISE INCIDENCE OF BREAST CANCER 
  Total number of early breast cancer cases      - 33 cases  
         Number of cases in stage 1                      -   6 cases 
         Number of cases in stage 2 a                  -   27 cases  
         Total number of locally advanced cases  - 153 cases.  
STAGE I
 STAGE IIA
STAGE IIB
STAGEIII
STAGEIV
74cases
27cases
6cases12cases
67cases
 
The other patients who presented in late stages 153 cases, were mostly 
unaware of the disease or they were taking native treatment until late 
stages. 
This shows a great need for health education programme and  
social awareness regarding breast cancer among the public. 
 
     AGE INCIDENCE 
 
                    AGE                NO. OF CASES 
       21 – 30 YRS                         2 
       31 – 40 YRS                         8 
       41 – 50 YRS                        10 
       51 – 60 YRS                         7 
        61 – 70 YRS                         6 
 
        
 There were no cases recorded below 28 years of age. 
        There was an increased incidence of breast cancer between the ages 
of       40- 50 years of age - 23 cases.  
         Most of the cases were between 41 – 50 years. The number of 
young women detected with breast cancer is increasing. (Early breast 
cancer triallist’s collaborative group, Lancet 1998)17 The reasons may be 
changes in life style, late child birth and beginning of lactation. There 
fore early diagnosis is mandatory. This indicates screening of population 
for detection of breast cancer in early stages with mammography is 
necessary after the age of 40yrs. 
 
AGE INCIDENCE IN EARLY BREAST CANCER 
0
2
4
6
8
10
12
21-30yrs 31-40yrs 41-50yrs 51-60yrs 61-70yrs
2cases
8cases
10cases
7cases
6cases
 
     
AGE AT MENARCHE 
                    10 - 12 years     - 7 cases 
                    12 -15 years      - 18 cases 
                    16- 18 years      - 8 cases 
  AGE AT MARRIAGE  
The average age at marriage was 20 years. All patients were married. 
  
  AGE AT FIRST CHILD BIRTH 
Less than 25 years                 - 26 cases 
More than 25 years                - 6 cases 
    PARITY 
Patients with 2 or more children     - 29 cases 
Patients with single child                - 3 cases 
Nullipara                                         - 1 case 
     DURATION OF BREAST FEEDING 
Most of them have breast fed their children for about 1 – 1 1/2 years. 
      Duration of breast feeding                  No. of cases 
           Less than 6 months                    6 cases 
            6 months to 1 yr                    8 cases 
            1 yr to 11/2  yrs                      18 cases 
 
There were no cases with family history of breast cancer. 
         Late menarche, early child birth, multiparity and period of breast 
feeding even though most of them have breast fed for more than 1 yr did 
not protect our patients. 
 MENOPAUSAL STATUS 
Number of premenopausal women               - 18 cases 
Number of postmenopausal women             - 15 cases 
 
    CLINICAL PRESENTATION 
The most common form of clinical presentation was mass in the breast. 
              SYMPTOMS             NO. OF CASES 
Lump breast                   33 
Mastalgia                     6 
Nipple discharge                     2 
Preexisting breast lesions                     2 
 
The commonest site was upper and outer quadrant in 23 cases. 
    SIDE WISE INCIDENCE 
          SIDE          NO. OF CASES 
       Left breast           18 cases 
       Right breast           15 cases 
 
         All patients had lump breast, 6 patients presented with mastalgia 
and 2 cases had nipple discharge. Two patients had pre existing breast 
lesions 
 – fibrocystic disease for which they were taking treatment. The 
commonest site of lump being the upper and outer quadrant in 23 cases 
and the side was left in 18 cases. 
 
      
 INVESTIGATIONS DONE: 
          Basic investigations were done for all cases including mammogram 
of the opposite breast and USG abdomen.  
FNAC                  -        33cases (was inconclusive in 2 cases) 
Tru-cut biopsy     -       2 cases out of which one was inconclusive 
Excision biopsy    -       It was confirmatory for a case of lobular    
                                     carcinoma. 
          All 33 cases underwent FNAC to confirm the diagnosis, out of 
which 31 cases – 93.9% were positive for breast cancer, the other 2 were 
inconclusive. The patients who had vague nodularity in the breast and 
inconclusive report of FNAC (2 cases) were diagnosed to have carcinoma 
when they were subjected to mammography. Out of the 2 inconclusive 
cases 1 case was confirmed by trucut biopsy and the other with excision 
biopsy (lobular carcinoma). 
 
 
 
 
 
 
 
 
 TREATMENT MODALITIES 
  TYPE OF SURGERY DONE             NO. OF CASES 
Modified radical mastectomy 
(Auchincloss’s) 
              21 
MRM with B/L oophorectomy               10 
Breast conservative surgery with 
axillary clearance 
                1 
MRM with TRAM flap                 1 
 
              Breast conservation surgery with radiotherapy being the 
treatment of choice for early breast cancer was advised for all patients. 
They were also told about the necessity for regular follow up after breast 
conservative surgery. Most of the patients were from poor socioeconomic 
group and from far away places. So they were not willing for breast 
conservation surgery. 
       Out of 33 cases 32 patients underwent modified radical mastectomy 
and one case was treated with breast conservation surgery with axillary 
clearance followed by radiotherapy, because both MRM and breast 
conservative surgery with radiotherapy have equal results in terms of 
local recurrence (Vicini, F. A., Recht, A.,Abner A, et al)22. One patient in 
stage IIa who requested for breast reconstruction was offered MRM 
withTRAM flap reconstruction.  Axillary clearance was done for all cases 
and sentinel lymph node sampling was not done in our study.  
 TYPE OF SURGERIES DONE FOR EARLY BREAST CANCER 
0
5
10
15
20
25
 A  B  C  D
A- MRM -21Cases.              
B- MRM with B/L Oophorectomy - 10 Cases. 
C- BCS with Axillary clearance - 1Case 
D- MRM with TRAM Flap – 1Case 
        The premenopausal patients were randomly selected for 
oophorectomy. It was not depending on the receptor status as we did the 
receptor analysis only in the post operative specimens. Of 10 cases who  
were subjected for oophorectomy 4 were positive for ER& PR receptors.  
  ADJUVANT THERAPY    
Number of cases received chemotherapy           - 27 - 81% 
Number of cases received hormone therapy      - 12  - 36% 
Number of cases received radiotherapy             - 1   - 3% 
        27 cases were treated with chemotherapy. The standard regimen 
used was AC regimen - Adriamycin 60 mg i.v and cyclophosphamide 600 
mg i.v given for single day. All patients were given 6 cycles, at an 
interval of 3 weeks.(J Natl. Cancer inst Mongr)18. Invariably all patients 
developed alopecia, 2 cases had mucositis and they were treated 
conservatively, and 1 case had anemia which was treated with two units 
of blood transfusion. All the patients completed their chemotherapy in 
due dates and there was no left outs    
         Hormone therapy was given for 12 cases, who had positive receptor 
status. Tamoxifen in the dose of 10 mg was given twice daily. 
         Post operative radiotherapy was given to the patient who was 
treated with breast conservative surgery. 
 
 RECEPTOR STATUS 
Number of cases with ER&PR receptor positive - 13 
Number of cases with ER&PR receptor negative - 20  
Premenopausal women with receptor positivity   - 5      (27.7%)                                     
Postmenopausal women with receptor positivity  - 8      ( 53.3%)                 
         Receptor study was done for all cases. Estrogen and progesterone 
receptors were positive in 13 cases, accounting for a total of 39%. 
Receptor positivity rate was more in post menopausal women – 53.3% 
when compared to pre menopausal women – 27.7 %. This indicates a 
better prognosis in post menopausal women and good response to 
tamoxifen therapy when compared to premenopausal women29. 
                       HISTOPATHOLOGICAL TYPES 
               HPE TYPES        NO. OF CASES 
  Invasive ductal carcinoma(Fig.21)               29 
  Invasive lobular carcinoma(Fig.22)                 1 
  Atrophic scirrhous carcinoma                 1 
 Medullary carcinoma                 1 
 Colloid carcinoma                 1 
 
         The commonest histopathological type encountered in this study 
was invasive ductal carcinoma in 29 cases. 
      HPE of axillary lymph nodes showed micrometastasis in 2 cases there 
was no cases with gross tumour invasion of nodes and there was no 
extracapsular invasion. Reactive hyperplasia was noted in 5 cases. 
 
 
 
 
 
 
 
 
 
 
 
INVASIVE DUCTAL CARCINOMA Fig.21 
 
 
 
INVASIVE LOBULAR CARCINOMA Fig.22 
 
 
 
 
FOLLOW UP 
   PERIOD OF FOLLOW UP   NO. OF CASES 
   More than 2 yrs              8 
   1 ½ - 2 yrs              10 
   1 – 1 ½ yrs               7 
   6 months – 1 yr               6 
  Less than 6 months               2 
 
      All patients were regularly followed up. As the cases were detected 
and treated in early stages there was no loco regional recurrence or distant 
metastasis5, 7. So detection of breast cancer in early stages by triple 
assessment - breast self examination, clinical breast examination and 
screening mammography is necessary.                                              
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Conclusion 
 
CONCLUSION 
 
    
 
1. The highest incidence of early breast cancer was between 41– 50 
years. This indicates the necessity for screening the population with 
mammography for detection of breast cancer in early stages after the 
age of 40 years. 
2. 93.9% of cases were diagnosed by FNAC. The commonest HPE type 
in early breast cancer was invasive ductal carcinoma. 
3. ER and PR positivity rates were more in post menopausal women 
53.3%.when compared to pre menopausal women 27.7% indicating 
better prognosis in post menopausal women. 
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Annexures 
 
 
 
 
 
 PROFORMA 
COIMBATORE MEDICAL COLLEGE HOSPITAL 
 
A study of the management of early Breast Cancer 
 
Name:      Age:   Sex:    IP.No: 
 
Address: 
 
DOA:     DOS:     DOD: 
 
Occupation:                                                           Marital Status: 
 
Educational Status:                                                Socio Economic Status: 
 
I. Clinically History 1. Presenting Symptoms 
 
When was the swelling noted: 
 
How did it appear: Acute / Insidious 
 
Progress: Increase in Size/ Decrease in Size/ No change 
 
 Any other swelling noticed: a.Same breast / Opposite breast 
 
         b. Ipsilateral LN / Contralateral LN 
 
Associated Symptoms: Pain, nipple discharge, nipple retraction, loss of 
weight 
 
 Symptoms suggestive of metastasis: Back Pain, Spontaneous Fracture, 
Headache /  
 
convulsions, Chest Symptoms, Jaundice, Opposite Breast Swelling 
 
Inflammatory symptoms: a. Systemic : Pyrexia, Sweating, Malaise, 
Anorexia 
 
     b. Local : Pain, Change in colour, Edema, 
Cellulitis. 
 
2. Past History  
 
 H/o. associated medical conditions like HT / DM / HD / TB, 
similar swelling in  
 
the breast, surgery for benign breast disease.  
 
3. Family History 
 
 H/o. breast cancer in I degree relatives 
 
4. Drug History 
 
 H/o. OCP intake / HRT, H/o previous exposure to radiation 
 
5. Menstrual History 
 
 Age at menarche, age at menopause, alteration in cycles 
  
6. Obstetric History 
 
 Parity :                                          Age of patient at l child birth: 
 
 History and duration of breast feeding : 
 
7. Material History 
 
 Age of the patient at marriage:                       No of partners: 
 
8. Personal History 
 
 History of any addiction - Smoking / alcohol 
 
 Dietetic history: 
 
 
 
 
 
II. Examination 
 
General Examination : Built / Pallor / lcterus / Pedal edema  
 
/lymphadenopathy. 
 
Breast:       A. Inspection 
 
                   B. Palpation 
 
                    C. Arm and chest wall 
 
  D. Lymph nodes 
 
  E. Opposite breast /Opposite axilla 
 
Other Systems  Abdomen: (i) Organomegaly,  (ii) Mass, (iii) PV / PR 
 
Respiratory system : 
 
Cardiovascular system : 
 
Central nervous system : 
 
Spine and cranium : 
 
Staging:    A. TNM                                                  B. Stage 
 
Biopsy:        FNAC                                                 Histopathology 
 
Other investigations 
 
 a. Radiology – Mammogram, X- ray chest, USG abdomen and 
pelvis, CT / MRI 
 
 b. Hematologic parameters 
 
 c. Receptor study 
 
 d. Bone scan 
 
Treatment plan:  
 
Treatment Done: 
 
 a. Surgery 
 
 b. Radiotherapy 
 
 c. Chemotherapy  
 
 d. Hormone therapy 
 
 e. Others 
 
Follow up: 
 
 
 
 
      
                                       
 
 
                                                                                       MASTER CHART 
 
S.NO NAME AGE I.P 
NO 
MENOPAUSAL  
STATUS 
STAGE  RECEPTOR 
STATUS 
TREATMENT HPE TYPE FOLLOW UP 
  1 Ayakkal 40 39350 Pre menopausal     II a ER & PR 
Negative 
Rt. MRM + CT Invasive 
ductal ca 
No recurrence or 
metastasis 
   2 Suguna 30 51258 Pre menopausal     II a ER& PR 
positive 
Lt. MRM+ 
Oophorectomy+CT 
Invasive 
ductal ca 
No recurrence or 
metastasis 
   3 Anthoniammal 40 14420 Pre menopausal     II a  ER& PR 
positive 
Lt. MRM+ 
Oophorectomy+CT 
Invasive 
ductal ca 
No recurrence or 
metastasis 
   4 Ammukutti 70 16831 Post menopausal      I ER& PR 
positive 
Lt. MRM+ HT Atrophic 
scirrhous ca 
No recurrence or 
metastasis 
   5 Lalitha 48 27514 Pre menopausal      II a ER & PR 
Negative 
Rt. MRM+ 
Oophorectomy+CT 
Invasive 
ductal ca in 
fibrocystic 
disease 
No recurrence or 
metastasis 
   6 Meena 28 28014 Pre menopausal     II a ER & PR 
Negative 
Rt. MRM+ 
Oophorectomy+CT 
Invasive 
ductal ca 
No recurrence or 
metastasis 
   7 Lingammal 55 28329 Post menopausal     II a  ER & PR 
Negative 
Rt. MRM + CT Invasive 
ductal ca 
No recurrence or 
metastasis 
   8 Shanthamani 40 46820 Pre menopausal    II a  ER & PR 
Negative 
Lt. MRM+ CT Invasive 
ductal ca 
No recurrence or 
metastasis 
   9 Ranjithamary 61 51632 Post menopausal     I ER& PR 
positive 
Lt. MRM+ HT Invasive 
ductal ca 
No recurrence or 
metastasis 
  10 Bakkiyam 57 53749 Post menopausal     II a ER & PR 
Negative 
Lt. MRM+ CT Invasive 
ductal ca 
No recurrence or 
metastasis 
  11 Pappathi 37 54302 Pre menopausal    II a  ER & PR 
Negative 
Lt. MRM 
Oophorectomy+CT 
Invasive 
ductal ca 
No recurrence or 
metastasis 
 
 
S.NO NAME AGE I.P 
NO 
MENOPAUSAL  
STATUS 
STAGE  RECEPTOR 
STATUS 
TREATMENT HPE TYPE FOLLOW UP 
  12 Krishnaveni 56 59683 Post menopausal     II a  ER & PR 
Negative 
Rt. MRM+ CT Invasive 
ductal ca ca 
No recurrence or 
metastasis 
 
  13 Manimekalai 40 645 Pre menopausal    II a  ER& PR 
positive 
Rt. MRM+ 
Oophorectomy+CT 
Invasive  
Ductal ca 
No recurrence or 
metastasis 
  14 Saraswathi 70 1016 Post menopausal      I ER& PR 
positive 
Rt. MRM + HT Invasive 
ductal ca 
No recurrence or 
metastasis 
  15 Mary 44 1965 Pre menopausal    II a  ER & PR 
Negative 
Rt.MRM with 
TRAM 
reconstruction+CT 
Invasive 
ductal ca 
No recurrence or 
metastasis 
  16 Jayalakshmi 42 2411 Pre menopausal    II a  ER & PR 
Negative 
Lt. MRM+ 
Oophorectomy+CT 
Invasive 
ductal ca 
No recurrence or 
metastasis 
  17 Mary 59 5673 Post menopausal     II a ER & PR 
Negative 
Lt. MRM+CT Invasive 
ductal ca 
No recurrence or 
metastasis 
  18 Pappathi 55 6106 Post menopausal     II a ER & PR 
Negative 
Lt. MRM+CT Invasive 
ductal ca 
No recurrence or 
metastasis 
  19 Amalorpava 
mary 
56 6125 Post menopausal     II a ER & PR 
Negative 
Rt. MRM+CT Invasive 
ductal ca 
No recurrence or 
metastasis 
  20 Mani 68 6153 Post menopausal     II a  ER& PR 
positive 
Rt.MRM+HT Medullary 
ca 
 No recurrence or 
metastasis 
  21 Thulasi 50 6375 Pre menopausal    II a  ER & PR 
Negative 
Rt. MRM+CT Invasive 
ductal ca 
No recurrence or 
metastasis 
 
 
  22 
   
Lalitha 
 
47 7119 Pre menopausal      I ER& PR 
positive 
Rt. Breast 
conservation 
surgery axillary 
clearance+RT+CT 
Invasive 
ductal ca 
Seroma.No 
recurrence or 
metastasis 
 
S.NO NAME AGE I.P 
NO 
MENOPAUSAL  
STATUS 
STAGE  RECEPTOR 
STATUS 
TREATMENT HPE TYPE FOLLOW UP 
  23 Palaniammal 49 8736 Post menopausal     II a ER & PR 
Negative 
Lt. MRM+CT Invasive 
ductal ca 
No recurrence or 
metastasis 
  24 Pappammal 65 10119 Post menopausal     II a ER & PR 
Positive 
Rt. MRM+HT Invasive 
ductal ca 
No recurrence or 
metastasis 
  25 Shailaja 50 10446 Pre menopausal    II a  ER & PR 
Positive 
Lt. MRM+ 
Oophorectomy+CT 
Invasive 
ductal ca 
No recurrence or 
metastasis 
  26 Shanthi 33 11550 Pre menopausal    II a  ER & PR 
Negative 
Lt. MRM+ 
Oophorectomy+CT 
Invasive 
ductal ca 
No recurrence or 
metastasis 
  27 Indirani 53 12873 Post menopausal     II a ER & PR 
Negative 
Lt. MRM+CT Invasive 
ductal ca 
No recurrence or 
metastasis 
  28 Karuppathal 67 17101 Post menopausal      I ER & PR 
Positive 
Lt. MRM+HT Invasive 
ductal ca 
No recurrence or 
metastasis 
  29 Saraswathi 45 24963 Pre menopausal      I ER & PR 
Negative 
Lt. MRM+ 
Oophorectomy+CT 
Invasive 
ductal ca 
No recurrence or 
metastasis 
  30 Kuttiammal 50 26641 Post menopausal     II a ER & PR 
Positive 
Lt. MRM+HT Colloid ca No recurrence or 
metastasis 
  31 Kandiammal 32 27793 Pre menopausal    II a  ER & PR 
Negative 
Rt. MRM+CT Invasive 
ductal ca 
No recurrence or 
metastasis 
  32 Indira 40 35430 Pre menopausal    II a  ER & PR 
Negative 
Lt. MRM+CT Invasive 
ductal ca 
No recurrence or 
metastasis 
  33 Shanthi 43 46286 Pre menopausal    II a  ER & PR 
Negative 
Rt. MRM+CT Invasive 
lobular ca 
No recurrence or 
metastasis 
 
 ER&PR - Estrogen and progesterone receptors,  MRM- Modified radical mastectomy,  CT– Chemotherapy, HT – Hormone therapy,                  
RT-Radiotherap 
